Compass Therapeutics (CMPX) Financials: Revenue & Earnings
CMPX$0.74-0.01 -1.08%
$133.14M
Market Cap
-1.83
P/E
10.70
Forward P/E
69
Score
Compass Therapeutics (CMPX) Financials: Revenue & Earnings
CMPX price $0.74 -0.01 -1.08%
- Ticker
- CMPX
- Price
- $0.74
- Change
- -0.01 -1.08%
- Market cap ?
- $133.14M
- P/E ?
- -1.83
- Forward P/E ?
- 10.70
- Dividend yield ?
- 0.00%
- Beta ?
- 0.91
- Sector
- Healthcare
- Industry
- Biotechnology
- Stocklytics score
- 69
- Value
- 59
- Quality
- 48
- Growth
- 100
Stocklytics score rationale: value 59, quality 48, growth 100.
Financials
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| 0 | 0 | 0 | 0 | 0 | 0 | 850000 | 0 |
Compass Therapeutics, Inc. is a biopharmaceutical firm focused on developing cancer treatments, with several therapeutic candidates currently in clinical trials. The company's work involves creating antibody-based medicines designed to address a variety of human health conditions. Among its leading clinical-stage programs are CTX-009, an experimental bispecific antibody engineered to inhibit the Delta-like ligand…
Fair value
CMPX fair value $1.41. Price $0.74. Price is 48% below fair value.
Fair value is an estimate of what one share is worth if future cash flows arrive as modeled. It is not a forecast of the share price. How discounted cash flow works.
Calculated with a 10-year free-cash-flow discount. Starting free cash flow 46.28K. Growth 20.00%. When analyst earnings forecasts are available, free cash flow in those years is forecast earnings times the company's usual conversion of earnings into free cash flow, kept between 60% and 130%. Years with fewer than 3 analyst estimates are left out. Growth then fades in a straight line to terminal growth by year 10, starting from the last well-covered year's growth, or from the pace across those years when the final year slows sharply, kept between 0% and 20%. Without those forecasts, year-1 growth is analyst revenue growth for the next full fiscal year, or 5-year historical revenue growth when that forecast is missing, held for five years, then fading in a straight line to terminal growth by year 10. Terminal growth 3.00%. Discount rate 9.33% (beta 0.9). Beta is kept between 0.8 and 2.0, which on its own would make the discount rate 8.7% to 15.3%. The rate is then capped at 12%. A cap is used because a discount above 12% pushes higher-beta stocks further from the price. The discount rate stays at least 5 percentage points above terminal growth. Shares 180.09M. Net debt -20.81M. The earnings value is next-12-months earnings per share, or trailing earnings when that forecast is missing, times the stock's own 10-year median P/E, kept between 8 and 40. Fewer than five years of history uses the sector's typical P/E. Fair value is the average of the cash-flow value and the earnings value when both exist. Model uncertainty is high when fair value is more than 60% from the price, or when most of the cash-flow value sits after year 10.
Earnings
| Date | EPS actual | EPS estimate | Revenue | Revenue estimate |
|---|---|---|---|---|
| 2026-11-04 | — | -0.12 | — | 229.25K |
| 2026-08-06 | -0.13 | -0.11 | — | -600.00K |
| 2026-05-05 | -0.10 | -0.10 | — | -818.18K |
| 2026-03-05 | -0.09 | -0.10 | — | -900.00K |
| 2025-11-05 | -0.08 | -0.14 | — | — |
| 2025-08-11 | -0.14 | -0.13 | — | — |
| 2025-05-08 | -0.12 | -0.12 | — | — |
| 2025-02-27 | -0.11 | -0.10 | — | — |
| 2024-11-12 | -0.08 | -0.11 | — | — |
| 2024-08-12 | -0.10 | -0.10 | 850.00K | — |
| 2024-05-13 | -0.08 | -0.11 | — | — |
| 2024-03-21 | -0.11 | -0.09 | 2.84M | — |
| 2023-11-09 | -0.08 | -0.11 | — | — |
| 2023-08-03 | -0.09 | -0.08 | — | — |
| 2023-05-04 | -0.06 | -0.11 | — | — |
| 2023-03-15 | -0.10 | -0.11 | — | — |
| 2022-11-09 | -0.12 | -0.11 | — | — |
| 2022-08-01 | -0.08 | -0.09 | — | — |
| 2022-05-09 | -0.07 | -0.11 | — | — |
| 2022-03-21 | -0.15 | -0.07 | — | — |
| 2021-11-12 | -0.10 | -0.12 | — | — |
| 2021-08-16 | -1.07 | — | — | — |
| 2021-04-30 | -0.14 | — | — | — |
| 2021-03-11 | -0.15 | — | — | — |
| 2021-03-05 | -0.14 | — | — | — |
| 2020-08-13 | -0.11 | — | — | — |
| 2020-06-08 | -0.12 | — | — | — |
| 2020-02-13 | -0.11 | — | — | — |
| 2019-11-13 | -0.16 | — | — | — |
| 2019-08-13 | -0.17 | — | — | — |
| 2019-07-01 | -2.15 | — | — | — |
Dividends
Yield 0.00%. Payout ratio 0.00%. Frequency —.
Safety score 37/100 · Watch. Payout ratio is 0% of earnings. Free-cash-flow coverage is not available, so this part stays neutral. No dividend history was found. There is no dividend yield.
| Ex-date | Dividend | Record | Payment | Frequency |
|---|---|---|---|---|
| No data yet. | ||||
Insider trades
| Date | Insider | Action | Shares | Price | Value |
|---|---|---|---|---|---|
| 2026-10-01 | Lerner Neil | Buy | 20.00K | $0.92 | 18.40K |
| 2026-09-24 | Lerner Neil | Buy | 2.50K | $1.14 | 2.85K |
| 2026-04-29 | Lerner Neil | Buy | 15.00K | $1.89 | 28.35K |
| 2026-04-29 | Anderman Jonathan | Buy | 25.00K | $1.89 | 47.25K |
| 2026-04-29 | Anderman Jonathan | Buy | 25.00K | $1.89 | 47.25K |
| 2026-04-29 | Lerner Neil | Buy | 15.00K | $1.89 | 28.35K |
| 2026-02-08 | Schuetz Thomas J. | Sell | 36.69K | $6.52 | 239.20K |
| 2026-01-09 | Schuetz Thomas J. | Sell | 46.78K | $5.35 | 250.26K |
| 2026-01-02 | Shin Barry | Buy | 670.00K | $5.17 | 3.46M |
| 2026-01-02 | Shin Barry | Buy | 125.00K | $5.17 | 646.25K |
| 2026-01-02 | Sirard Cynthia | Buy | 1.00M | $5.17 | 5.17M |
| 2026-01-02 | Schuetz Thomas J. | Buy | 250.00K | $5.17 | 1.29M |
| 2026-01-02 | Schuetz Thomas J. | Buy | 2.00M | $5.17 | 10.34M |
| 2026-01-02 | Prasad Arjun | Buy | 1.00M | $5.17 | 5.17M |
| 2026-01-02 | LINDAHL RICHARD S | Buy | 90.00K | $5.17 | 465.30K |
| 2026-01-02 | Chiniara Ellen | Buy | 90.00K | $5.17 | 465.30K |
| 2026-01-02 | Lerner Neil | Buy | 435.00K | $5.17 | 2.25M |
| 2026-01-02 | Lerner Neil | Buy | 62.50K | $5.17 | 323.12K |
| 2026-01-02 | GRAY MARY ANN | Buy | 90.00K | $5.17 | 465.30K |
| 2026-01-02 | Boylan James P | Buy | 90.00K | $5.17 | 465.30K |
| 2026-01-02 | GORDON CARL L | Buy | 90.00K | $5.17 | 465.30K |
| 2026-01-02 | Ferneau Philip | Buy | 90.00K | $5.17 | 465.30K |
| 2026-01-02 | Anderman Jonathan | Buy | 720.00K | $5.17 | 3.72M |
| 2026-01-02 | Anderman Jonathan | Buy | 150.00K | $5.17 | 775.50K |
| 2026-01-02 | Sirard Cynthia | Other | 0 | — | — |
| 2026-01-02 | Prasad Arjun | Other | 0 | — | — |
| 2025-11-16 | Schuetz Thomas J. | Sell | 44.02K | $4.83 | 212.64K |
| 2025-05-27 | Schuetz Thomas J. | Buy | 10.00K | $2.11 | 21.10K |
| 2025-04-09 | GORDON CARL L | Sell | 3.57M | $1.59 | 5.68M |
| 2025-04-09 | ORBIMED ADVISORS LLC | Sell | 3.57M | $1.59 | 5.68M |
| 2025-04-07 | Anderman Jonathan | Buy | 20.00K | $1.54 | 30.80K |
| 2025-04-07 | Lerner Neil | Buy | 20.00K | $1.42 | 28.40K |
| 2025-02-11 | Shin Barry | Buy | 250.00K | $3.65 | 912.50K |
| 2025-02-11 | Schuetz Thomas J. | Buy | 1.50M | $3.65 | 5.47M |
| 2025-02-11 | LINDAHL RICHARD S | Buy | 40.00K | $3.65 | 146.00K |
| 2025-02-11 | Lerner Neil | Buy | 200.00K | $3.65 | 730.00K |
| 2025-02-11 | GRAY MARY ANN | Buy | 40.00K | $3.65 | 146.00K |
| 2025-02-11 | Ferneau Philip | Buy | 40.00K | $3.65 | 146.00K |
| 2025-02-11 | Chiniara Ellen | Buy | 40.00K | $3.65 | 146.00K |
| 2025-02-11 | Anderman Jonathan | Buy | 280.00K | $3.65 | 1.02M |
| 2025-02-11 | GORDON CARL L | Buy | 40.00K | $3.65 | 146.00K |
| 2025-02-11 | Boylan James P | Buy | 40.00K | $3.65 | 146.00K |
| 2025-02-08 | Schuetz Thomas J. | Sell | 41.69K | $3.50 | 145.90K |
| 2025-01-09 | Schuetz Thomas J. | Sell | 58.05K | $1.86 | 107.98K |
| 2024-12-09 | Shin Barry | Buy | 400.00K | $1.65 | 660.00K |
| 2024-12-09 | Shin Barry | Buy | 400.00K | $1.65 | 660.00K |
| 2024-12-09 | Shin Barry | Other | 0 | — | — |
| 2024-12-09 | Lerner Neil | Other | 0 | — | — |
| 2024-12-09 | Lerner Neil | Other | 175.00K | $1.20 | 210.00K |
| 2024-12-09 | Lerner Neil | Other | 90.00K | $5.00 | 450.00K |
| 2024-12-09 | Lerner Neil | Other | 85.00K | $3.83 | 325.55K |
| 2024-12-09 | Lerner Neil | Other | 50.00K | $2.40 | 120.00K |
| 2024-12-09 | Lerner Neil | Other | 80.00K | $3.93 | 314.40K |
| 2024-12-09 | Lerner Neil | Other | 40.00K | $3.50 | 140.00K |
| 2024-12-09 | Lerner Neil | Other | 60.00K | $1.57 | 94.20K |
| 2024-08-13 | Anderman Jonathan | Buy | 300.00K | $1.20 | 360.00K |
| 2024-08-01 | Anderman Jonathan | Sell | 0 | — | — |
| 2024-08-01 | Anderman Jonathan | Sell | 80.00K | $1.57 | 125.60K |
| 2024-08-01 | Anderman Jonathan | Sell | 85.00K | $3.83 | 325.55K |
| 2024-08-01 | Anderman Jonathan | Sell | 80.00K | $3.93 | 314.40K |
| 2024-08-01 | Anderman Jonathan | Sell | 130.00K | $4.05 | 526.50K |
| 2024-08-01 | Anderman Jonathan | Sell | 50.00K | $2.40 | 120.00K |
| 2024-03-08 | Boylan James P | Buy | 40.00K | $1.96 | 78.40K |
| 2024-02-09 | GRAY MARY ANN | Buy | 40.00K | $1.57 | 62.80K |
| 2024-02-09 | LINDAHL RICHARD S | Buy | 40.00K | $1.57 | 62.80K |
| 2024-02-09 | GORDON CARL L | Buy | 40.00K | $1.57 | 62.80K |
| 2024-02-09 | Chiniara Ellen | Buy | 40.00K | $1.57 | 62.80K |
| 2024-02-09 | Ferneau Philip | Buy | 40.00K | $1.57 | 62.80K |
| 2024-02-08 | Bisker-Leib Vered | Sell | 49.20K | $1.45 | 71.34K |
| 2024-02-08 | Schuetz Thomas J. | Sell | 44.78K | $1.45 | 64.93K |
| 2024-01-09 | Bisker-Leib Vered | Buy | 1.75M | $1.93 | 3.38M |
| 2024-01-09 | Bisker-Leib Vered | Buy | 1.75M | $1.93 | 3.38M |
| 2024-01-09 | Schuetz Thomas J. | Buy | 637.50K | $1.93 | 1.23M |
| 2024-01-09 | Schuetz Thomas J. | Buy | 637.50K | $1.93 | 1.23M |
| 2023-11-17 | Bisker-Leib Vered | Sell | 64.42K | $1.50 | 96.62K |
| 2023-11-17 | Schuetz Thomas J. | Sell | 44.02K | $1.50 | 66.04K |
| 2023-04-21 | LINDAHL RICHARD S | Buy | 50.00K | $2.91 | 145.50K |
| 2023-04-21 | LINDAHL RICHARD S | Other | 0 | — | — |
| 2023-03-10 | Schuetz Thomas J. | Buy | 10.00K | $3.37 | 33.70K |
| 2023-02-27 | Schuetz Thomas J. | Buy | 20.00K | $3.98 | 79.60K |
| 2023-02-15 | Schuetz Thomas J. | Buy | 20.00K | $3.86 | 77.20K |
| 2023-02-08 | WURZER DAVID M | Buy | 50.00K | $3.93 | 196.50K |
| 2023-02-08 | WURZER DAVID M | Other | 0 | — | — |
| 2023-02-08 | Chiniara Ellen | Buy | 40.00K | $3.93 | 157.20K |
| 2023-02-08 | GRAY MARY ANN | Buy | 40.00K | $3.93 | 157.20K |
| 2023-02-08 | GORDON CARL L | Buy | 60.00K | $3.93 | 235.80K |
| 2023-02-08 | Ferneau Philip | Buy | 50.00K | $3.93 | 196.50K |
| 2023-02-08 | Schuetz Thomas J. | Buy | 500.00K | — | — |
| 2023-02-08 | Schuetz Thomas J. | Buy | 700.00K | $3.93 | 2.75M |
| 2023-02-08 | Bisker-Leib Vered | Buy | 400.00K | — | — |
| 2023-02-08 | Bisker-Leib Vered | Buy | 600.00K | $3.93 | 2.36M |
| 2023-01-31 | Schuetz Thomas J. | Buy | 20.00K | $4.05 | 81.00K |
| 2023-01-24 | Schuetz Thomas J. | Buy | 20.00K | $4.19 | 83.80K |
| 2022-11-25 | Bisker-Leib Vered | Sell | 2 | $4.36 | 9 |
| 2022-11-23 | Bisker-Leib Vered | Sell | 9.57K | $4.30 | 41.15K |
| 2022-11-22 | Bisker-Leib Vered | Sell | 14.93K | $4.19 | 62.55K |
| 2022-11-08 | ORBIMED ADVISORS LLC | Buy | 402.00K | $3.21 | 1.29M |
| 2022-11-08 | GORDON CARL L | Buy | 402.00K | $3.21 | 1.29M |
| 2022-11-04 | Boylan James P | Other | — | — | — |
| 2022-11-04 | Boylan James P | Other | 0 | — | — |
Institutional holders
Latest filed quarter: Q2 2026.
Institutions holding: 222, holders +13 vs prior quarter. Ownership 88.87%.
| Holder | Shares | Change | Change % | Value |
|---|---|---|---|---|
| TANG CAPITAL MANAGEMENT LLC | 17.99M | 1.20M | +7.15% | 39.40M |
| ORBIMED ADVISORS LLC | 15.22M | 0 | 0.00% | 33.33M |
| MONTANOVA CAPITAL, LLC | 14.10M | -206.22K | -1.44% | 30.88M |
| BLACKROCK, INC. | 11.28M | 1.78M | +18.68% | 24.71M |
| STATE STREET CORP | 9.95M | 3.26M | +48.67% | 21.80M |
| ENAVATE SCIENCES GP, LLC | 7.79M | 0 | 0.00% | 17.06M |
| VIVO CAPITAL, LLC | 7.76M | -1.79M | -18.74% | 16.99M |
| VANGUARD CAPITAL MANAGEMENT LLC | 6.12M | 81.61K | +1.35% | 13.40M |
| PALO ALTO INVESTORS LP | 5.83M | 4.32M | +285.06% | 12.77M |
| MILLENNIUM MANAGEMENT LLC | 4.71M | 3.87M | +456.98% | 10.32M |
| GEODE CAPITAL MANAGEMENT, LLC | 3.82M | 249.42K | +6.99% | 8.36M |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 3.77M | 2.69M | +248.31% | 8.26M |
| QUBE RESEARCH & TECHNOLOGIES LTD | 3.69M | 1.14M | +44.59% | 8.08M |
| BLUE OWL CAPITAL HOLDINGS LP | 3.62M | 682.55K | +23.20% | 7.94M |
| CITADEL ADVISORS LLC | 3.57M | 3.50M | +4712.23% | 7.82M |
| GOLDMAN SACHS GROUP INC | 3.53M | 1.54M | +76.96% | 7.73M |
| ROCK SPRINGS CAPITAL MANAGEMENT LP | 3.52M | 219.62K | +6.64% | 7.72M |
| AQR CAPITAL MANAGEMENT LLC | 3.51M | 3.31M | +1650.82% | 7.69M |
| BIRCHVIEW CAPITAL, LP | 1.68M | 209.13K | +14.27% | 3.67M |
| KINGDON CAPITAL MANAGEMENT, L.L.C. | 1.40M | 1.40M | New | 3.07M |
| FISHER ASSET MANAGEMENT, LLC | 1.39M | 43.63K | +3.24% | 3.05M |
| ROYCE & ASSOCIATES LP | 1.34M | -283.02K | -17.47% | 2.93M |
| FMR LLC | 1.21M | -589.52K | -32.72% | 2.65M |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | 1.19M | -7.30M | -86.02% | 2.60M |
| ACADIAN ASSET MANAGEMENT LLC | 1.16M | 1.16M | New | 2.54M |
Earnings and financials
Compass Therapeutics, Inc. (CMPX) trades at $0.74, with a market cap of $133.14M and a trailing P/E of -1.83. Revenue below is the annual history on file. It describes what the business has already reported. It is not a forecast and it is not a recommendation.
Financials
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| 0 | 0 | 0 | 0 | 0 | 0 | 850000 | 0 |
Insights · Dividends · Forecast · Financials · Learn